Inhalation Sciences receives IRS order worth SEK 212,000 from global leader in generics and biosimilars

(Stockholm, Sweden, 10 January 2025) Inhalation Sciences AB (ISAB) has received an order worth SEK 212,000 from a returning client, a global leader in generics and biosimilars, for an Inhalation Research Services (IRS) project.

The client has chosen ISAB’s unique technology for a feasibility test and given a positive outcome, additional IRS are being planned.

CEO Manoush Masarrat comments: "We are delighted that our technology has been selected by such an expert and experienced team. This is important work, and we look forward to working with this project. We see good potential here for further projects and collaborations moving forward."

For more information about Inhalation Sciences, please contact:

Manoush Masarrat, CEO

E-mail: [email protected]

Mobile: +46 (0)73 628 9153

About Inhalation Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company’s patented lab instruments PreciseInhale^® and DissolvIt^® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.